IRIS UniCatt

Colafigli, Manuela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.568
EU - Europa 2.891
AS - Asia 2.063
SA - Sud America 392
Continente sconosciuto - Info sul continente non disponibili 83
AF - Africa 57
OC - Oceania 3
AN - Antartide 1
Totale 9.058
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.460
SG - Singapore 950
DE - Germania 883
CN - Cina 541
FR - Francia 437
SE - Svezia 368
PL - Polonia 330
BR - Brasile 307
UA - Ucraina 238
IT - Italia 212
VN - Vietnam 149
GB - Regno Unito 131
IE - Irlanda 101
IN - India 92
ID - Indonesia 65
CA - Canada 56
TR - Turchia 56
FI - Finlandia 55
RU - Federazione Russa 42
HK - Hong Kong 41
AR - Argentina 36
JP - Giappone 36
BD - Bangladesh 35
MX - Messico 30
ZA - Sudafrica 21
BE - Belgio 14
ES - Italia 13
IQ - Iraq 13
NL - Olanda 12
VE - Venezuela 12
PH - Filippine 11
MA - Marocco 10
LT - Lituania 9
PK - Pakistan 9
CO - Colombia 8
IR - Iran 8
AT - Austria 7
EC - Ecuador 7
JM - Giamaica 7
SA - Arabia Saudita 7
IL - Israele 6
CZ - Repubblica Ceca 5
EG - Egitto 5
EU - Europa 5
JO - Giordania 5
KE - Kenya 5
KZ - Kazakistan 5
PE - Perù 5
PY - Paraguay 5
CL - Cile 4
DZ - Algeria 4
GR - Grecia 4
KR - Corea 4
PT - Portogallo 4
TN - Tunisia 4
UY - Uruguay 4
AL - Albania 3
BG - Bulgaria 3
BO - Bolivia 3
CH - Svizzera 3
CR - Costa Rica 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
HN - Honduras 3
MD - Moldavia 3
MY - Malesia 3
NI - Nicaragua 3
PS - Palestinian Territory 3
QA - Qatar 3
AM - Armenia 2
AU - Australia 2
AZ - Azerbaigian 2
CI - Costa d'Avorio 2
ET - Etiopia 2
GE - Georgia 2
KG - Kirghizistan 2
NO - Norvegia 2
NP - Nepal 2
RS - Serbia 2
TW - Taiwan 2
AG - Antigua e Barbuda 1
AO - Angola 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BW - Botswana 1
CY - Cipro 1
EE - Estonia 1
HU - Ungheria 1
IM - Isola di Man 1
IS - Islanda 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
MM - Myanmar 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
OM - Oman 1
Totale 8.974
Salva come PNG Salva come JPEG
Città #
Singapore 503
Chandler 469
Ashburn 411
Kraków 317
San Jose 262
Jacksonville 164
New York 159
San Mateo 120
Dublin 99
Beijing 90
Nanjing 90
Dearborn 73
Houston 67
Los Angeles 64
Wilmington 63
Lauterbourg 61
Jakarta 59
Milan 55
Ann Arbor 54
Ho Chi Minh City 47
Nürnberg 47
Boston 46
Lawrence 45
Cattolica 43
Dallas 42
Izmir 41
Redmond 41
Hanoi 38
Nanchang 37
Hong Kong 36
Woodbridge 32
Munich 31
Tokyo 30
Redwood City 29
Frankfurt am Main 28
Hefei 27
The Dalles 26
Santa Clara 24
Lancaster 23
Orem 23
Atlanta 22
Bremen 21
Changsha 20
Fairfield 20
Moscow 20
Ottawa 19
Buffalo 18
Chicago 18
Seattle 17
São Paulo 17
University Park 17
Shenyang 16
Boardman 15
Princeton 15
Brussels 14
San Francisco 14
Hebei 13
Johannesburg 13
Kunming 13
London 13
Montreal 13
Guangzhou 12
Mountain View 12
Brooklyn 11
Fremont 11
Marseille 11
Norwalk 11
Chennai 10
Düsseldorf 10
Jinan 10
Leawood 10
Poplar 10
Rome 10
Shanghai 10
Augusta 9
Denver 9
Falls Church 9
Hangzhou 9
Jiaxing 9
Phoenix 9
Pune 9
Toronto 9
Verona 9
Warsaw 9
Washington 9
Memphis 8
Nuremberg 8
Paris 8
Portsmouth 8
Amsterdam 7
Da Nang 7
Manchester 7
Porto Alegre 7
Rio de Janeiro 7
Tianjin 7
Biên Hòa 6
Detroit 6
Helsinki 6
Las Vegas 6
Mexico City 6
Totale 4.605
Salva come PNG Salva come JPEG
Nome #
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 271
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. 270
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 233
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 214
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 211
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 201
Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance 198
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 198
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 197
Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. 196
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study 194
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 189
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 181
Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. 180
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy 179
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 174
Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar year: a cohort study 172
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 171
The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study 169
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 168
Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction? 159
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 159
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 158
Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. 157
Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1 157
Cardiovascular risk factors and carotid intima-media thickness are associated with low cognitive performance in HIV-infected patients 157
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study 154
Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. 151
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group 148
Long term follow-up of Nevirapine-treated patients in a single centre cohort 147
Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure. 146
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 145
Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients 144
HIV-infected patients show impaired cellular immune response to influenza vaccination, compared to healthy subjects 144
Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients 143
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients 143
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 141
Prevalence of transmitted HIV-1 drug resistance in HIV-1 infected patients in Italy: evolution over 12 years and predictors 141
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: A multicenter observational study 141
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV 140
Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors 137
Exploratory analysis for the evaluation of estimated glomerular filtration rate, cholesterol and triglycerides after switching from tenofovir/emtricitabine plus atazanavir/ritonavir (ATV/r) to abacavir/lamivudine plus ATV/r in patients with preserved renal function 137
HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjects 136
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 131
Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine 126
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 125
Interpretation systems for genotypic drug resistance of HIV-1 124
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis 122
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort 120
Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study 109
Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy 109
Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors, non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: a multicenter retrospective cohort study 106
Overall Tolerability of Integrase Inhibitors in Clinical Practice: Results from a Multicenter Italian Cohort 105
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study 104
Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study 93
Survival in HIV-infected patients after a cancer diagnosis in the cART era: Results of an Italian multicenter study 91
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: A multicenter retrospective cohort study from 2007 to 2015 84
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 80
Combining epidemiological and genetic networks signifies the importance of early treatment in HIV-1 transmission 78
Totale 9.058
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.253
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.253
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022504 0 52 13 41 24 28 9 104 17 46 72 98
2022/20231.141 170 177 82 185 82 143 25 92 129 5 38 13
2023/2024570 19 151 9 59 23 169 17 4 6 9 69 35
2024/2025991 17 29 70 48 135 44 20 56 155 99 173 145
2025/20262.600 409 55 157 298 509 117 450 146 169 181 66 43
2026/2027278 98 180 0 0 0 0 0 0 0 0 0 0
Totale 9.058